Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.07 USD | +2.48% | +2.99% | -45.95% |
04-04 | Top Premarket Gainers | MT |
03-19 | H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 32.62M 44.58M |
---|---|---|---|---|---|
Net income 2024 * | -15M -20.5M | Net income 2025 * | -26M -35.54M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.13
x | P/E ratio 2025 * |
-1.26
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.74% |
Latest transcript on Acurx Pharmaceuticals, Inc.
1 day | +2.48% | ||
1 week | +2.99% | ||
Current month | -15.51% | ||
1 month | -0.48% | ||
3 months | -46.51% | ||
6 months | -56.14% | ||
Current year | -45.95% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Shawah
FOU | Founder | 57 | 17-06-30 |
David Luci
FOU | Founder | 57 | 17-06-30 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert de Luccia
FOU | Founder | 78 | 17-06-30 |
Joseph Scodari
BRD | Director/Board Member | 71 | 21-06-23 |
Thomas Harrison
BRD | Director/Board Member | 76 | 21-06-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.07 | +2.48% | 28,608 |
24-04-25 | 2.02 | -0.49% | 85,176 |
24-04-24 | 2.03 | -0.49% | 16,644 |
24-04-23 | 2.04 | +3.03% | 29,788 |
24-04-22 | 1.98 | -1.49% | 52,022 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.95% | 32.62M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ACXP Stock